VivoSeq
Immunology

Autoimmune Encephalitis

18

Pipeline Programs↗

6

Active Trials↗

12

Companies Involved↗

Autoimmune Encephalitis is an emerging landscape with 18 programs across 12 companies. The most active players are Triax, CSL Behring, ImCheck Therapeutics. 2 therapies are approved with 5 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

46/100

Pipeline Velocity

6/100

Mech. Concentration

25/100

Completion Rate

56/100

Attrition Rate

24/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

T

Triax

1 program

Phase 2CSL Behring logo

CSL Behring

1 program

Phase 2I

ImCheck Therapeutics

1 program

Phase 2UCB logo

UCB

2 programs

Phase 2N

Nihon Pharmaceutical Co., Ltd

2 programs

Phase 3Novartis logo

Novartis

1 program

Phase 3

Pipeline

Programs by Phase

Analysis

Modality Breakdown

70%

Small molecule

16 of 23 classified programs — the dominant modality here.

30%ALL OTHERSMonoclonal antibody522%Protein / enzyme14%Cell therapy14%

Small molecule leads; the ring shows all 23 classified programs, each share of the total. Modality classified for 100% of 25 pipeline programs.

Analysis

Trial Status

17

clinical trials

Completed5 · 29%
Recruiting4 · 24%
Withdrawn2 · 12%
Unknown status2 · 12%
Terminated2 · 12%
Not yet recruiting1 · 6%
Other1 · 6%

Clinical Trials

Trial Activity

17 trials

Safety and Efficacy of Combined B Cell Depleting theRapy And Daratumumab In Autoimmune Encephalitis
Recruiting·TThe First People's Hospital of Changzhou·Phase 3·NCT06867991·200 enrolled
Trial to Evaluate Efficacy and Safety of Bortezomib in Patients With Severe Autoimmune Encephalitis
Recruiting·JJena University Hospital·Phase 2·NCT03993262·50 enrolled
Characterization of Immune-response in Autoimmune Encephalitis and Paraneoplastic Neurological Syndromes
Recruiting·HHospices Civils de Lyon·N/A·NCT05772611·180 enrolled
Paraneoplastic Neurological Syndromes and Autoimmune Encephalitis Collection
Recruiting·HHospices Civils de Lyon·N/A·NCT05198661·3,500 enrolled
A Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter Basket Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Patients With Anti-N-methyl-D-aspartic Acid Receptor (NMDAR) or Anti-leucine-rich Glioma-inactivated 1 (LGI1) Encephalitis
Active, not recruiting·Roche logoRoche·Phase 3·NCT05503264·122 enrolled
hUC-MSC-Exo Therapy for Autoimmune Encephalitis
Not yet recruiting·XXuanwu Hospital, Beijing·Phase 1/2·NCT07131683·38 enrolled
CPI Combination Therapy for Autoimmune Encephalitis
Completed·XXuanwu Hospital, Beijing·N/A·NCT03542279·70 enrolled
To Explore Cognitive Neural Mechanism of Autoimmune Encephalitis by Using Neuropsychological Tests and Multi-modal MRI
Completed·FFirst Affiliated Hospital of Zhejiang University·N/A·NCT03530462·22 enrolled
Safety and Efficacy of IGIV 10% in Patients With Autoimmune Encephalitis:
Completed·GGreen Cross Corporation·Phase 2·NCT04175522·23 enrolled
Efficacy and Safety of Adjunctive Minocycline in the Treatment of Autoimmune Encephalitis
Completed·XXijing Hospital·Phase 2·NCT06033846·60 enrolled
IL-2 in Refractory Autoimmune Encephalitis
Completed·SSeoul National University Hospital·Phase 1/2·NCT02714959·10 enrolled
Efficacy of Ocrelizumab in Autoimmune Encephalitis
Terminated·UUniversity of Texas Southwestern Medical Center·Phase 2·NCT03835728·3 enrolled
A Study to Test the Efficacy, Safety, and Pharmacokinetics of Rozanolixizumab in Adult Study Participants With Leucine-Rich Glioma Inactivated 1 Autoimmune Encephalitis
Terminated·UCB logoUCB·Phase 2·NCT04875975·12 enrolled
Effect of Erythropoietin in Refractory Autoimmune Encephalitis Patients
Withdrawn·SSeoul National University Hospital·Phase 4·NCT03004209
Effect of Vigabatrin in Refractory Autoimmune Encephalitis Patients
Withdrawn·SSeoul National University Hospital·N/A·NCT03003143
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)